Overview
Isabel Hecht is a Pediatric Hematologist Oncology provider in Washington, Washington, D.c.. Her top area of expertise is Immune Thrombocytopenic Purpura (ITP).
Specialties
Licenses
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- EPO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- INSURANCE PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE ASSISTANCE PROGRAM
- MEDICARE MAPD
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
Additional Areas of Focus
Hecht has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Reuven Schore is a Pediatric Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Schore is highly rated in 3 conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Juvenile Myelomonocytic Leukemia (JMML), and Febrile Neutropenia.
Johns Hopkins Children's Center
"In her first decade as a pediatric oncologist, Dr. Symons already has shown an impressive ability to juggle multiple research projects, in addition to caring for patients. One of Dr. Symons' research pursuits focuses on using a novel immunotherapy approach to treating both solid tumors and hematologic (blood-borne) malignancies. The basis of her work stems from the theory that cancer patients' immune systems should recognize tumor cells as foreign and destroy them. This doesn't happen, theorizes Dr. Symons, because the immune system attacks only those cells it perceives as dangerous—not cancer cells, which it sees simply as foreign. That's where her research comes into play. Evaluating an experimental therapy, Dr. Symons is pairing donor lymphocytes (white blood cells that activate the body's immune system) with chemotherapy to determine if this combination will ""awaken"" patients' immune systems to the danger of existing cancer cells and, in turn, elicit an immune response. In a separate yet equally compelling research endeavor, Dr. Symons is working to increase the availability of donors for children whose cancer requires bone marrow transplants (BMTs) as a potentially lifesaving treatment. ""It can be challenging to find a 'matched' donor,"" says Dr. Symons, who explains that only about 40 percent of patients who require a BMT find a matched donor. ""Sometimes, we don't have the benefit of time, because remissions can be short-lived. But almost all patients have a half-matched donor: a parent, sibling, or child,"" adds Dr. Symons, who is examining ways to reduce BMT-related complications ordinarily associated with half-matched donors after ablative (high dose) chemotherapy. ""Like anything else that's new, it will take some time to prove that this is a feasible option that's safe,"" she says. But she's optimistic. ""It has the potential to revolutionize BMT."" Dr. Symons knows it's worth the wait. ""Seeing the research I do in the lab translate into clinical trials, then seeing patients in these trials survive long term, is incredibly rewarding,"" she says.". Dr. Symons is highly rated in 2 conditions, according to our data. Her top areas of expertise are Graft Versus Host Disease (GvHD), Aplastic Anemia, Anemia, Leukemia, and Bone Marrow Transplant.
Johns Hopkins Children's Center
Dr. Donald Small is the Kyle Haydock Professor of Oncology. He holds joint appointments in Pediatrics and Cellular and Molecular Medicine and Human Genetics. He also directs the Johns Hopkins/National Cancer Institute Pediatric Hematology/Oncology Fellowship program. Dr. Small received his undergraduate, and then M.D. and Ph.D. degrees from the Johns Hopkins University in 1979 and 1985. His Ph.D. research was conducted with Bert Vogelstein in the Oncology Department and his postdoctoral research with Tom Kelly in the Molecular Biology and Genetics Department. He trained in pediatrics and pediatric hematology/oncology at Johns Hopkins and joined the faculty in 1990. Dr. Small’s laboratory was the first to clone the human FLT3 gene that is the most frequently mutated gene in acute myeloid leukemia (AML) and results in very poor chances of cure for these patients. The investigations of FLT3 led Dr. Small and his team to discover drugs able to inhibit the cancer-generating activity of this important gene. His laboratory showed that a new class of drugs known as tyrosine kinase inhibitors could kill FLT3-affected cells, thus developing one of the earliest molecularly targeted cancer therapies. They then developed a test that enabled them to screen a host of additional kinase inhibitors and find several with great potency against FLT3. His group also led the first clinical trials investigating the use of a FLT3 inhibitor in adult relapsed and refractory FLT3 mutant AML, and determined how best to combine these drugs with chemotherapy. They also helped design the first pediatric trials of FLT3 inhibitors in pediatric AML and infant ALL. Dr. Small’s lab continues to investigate leukemic processes and the role of stem cells in governing the activities of the FLT3 gene in leukemia. Dr. Small is highly rated in 2 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, and Acute Lymphoblastic Leukemia (ALL).
Frequently Asked Questions about Isabel V. Hecht, NP
How do I make an appointment with Isabel V. Hecht, NP?
You can book an appointment with Isabel V. Hecht, NP by calling their office at 617-840-7290. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
What conditions does Isabel V. Hecht, NP specialize in?
While Isabel V. Hecht, NP is a Pediatric Hematology Oncology, they have specific expertise in Immune Thrombocytopenic Purpura (ITP). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Hematology Oncology.
Does Isabel V. Hecht, NP accept my insurance?
Isabel V. Hecht, NP accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-840-7290 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers